AtbFinder: A New Diagnostic Tool for the Selection of Optimal Antibiotics for Patients with Drug-Resistant Bacterial Infections

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Existing methods for antibiotic selection are based on outdated and inaccurate microbiological principles, causing millions of inappropriate antibiotic selections and hundreds of thousands of preventable deaths, particularly in patients with respiratory infections. These tests take days and fail to select effective antibiotics against multidrug resistant pathogens because they do not account for critical characteristics of “real-life” infections. AtbFinder is a novel rapid culture-based diagnostics test system, employing a novel paradigm of antibiotic selection.  It mimics conditions of antibiotics  interactions  with bacteria within a host by remodeling polymicrobial biofilms from the site of infection in which interbacterial interactions that affect bacterial sensitivity to antibiotics are modulated, and testing antibiotics taken at concentrations that can be achieved in affected tissue or organ. AtbFinder selects antibiotics that treat the bacterial community at the site of infection as a whole and  enables: (i)The selection of antibiotics effective against extensively drug-resistant polymicrobial biofilm challenged infections (ii)The reporting of results in <4 hours, saving over 44 hours compared to conventional methods.

Here, we, for the first time, present findings from a 3 year long clinical study reporting the performance of antibiotic therapy selected based on recommendations of AtbFinder for patients with multidrugresistant bacteria in patients with cystic fibrosis.

Results: Antibiotic optimization aided by the AtbFinder led to: Eradicated drug-resistant P.aeruginosa Infections in 73% of cases; FEV1% increased up to 27%; Decreased the incidence of hospitalizations by 100%; Normalized WBC and CRP inflammatory markers, that correlate with lung injury; Number of systemic antibiotic courses was reduced from 355 to 178.

Conclusion: Antibiotic optimization with AtbFinder results in progressive eradication of P.aeruginosa from airways of patients with CF.

 

Learning objectives:

1. Selection of antibiotics that treat the bacterial community at the site of infection as a whole is a better option for patients.

2. Mult-idrug resistant bacteria can be treated with antibiotics active against bacteria that support their growth 


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
JAN 13, 2022 9:00 AM PST
C.E. CREDITS
JAN 13, 2022 9:00 AM PST
Date: January 13, 2022 Time: 09:00am (PST), 12:00pm (EST) Recently, the Infectious Disease Society of America released guidance on how to approach treatment of infections caused by multidrug...
DEC 14, 2021 6:00 AM PST
C.E. CREDITS
DEC 14, 2021 6:00 AM PST
Date: December 14, 2021 Time: 6:00am (PST), 9:00am (EST) Hepatitis E virus (HEV) is a single-stranded positive-sense RNA virus and is a leading cause of acute viral hepatitis worldwide. The...
Loading Comments...
Show Resources